Want to see TSE:THRM full AI Analyst Report?
THRM Stock Chart & Stats
C$0.05
>-C$0.01(-3.64%)
At close: 4:00 PM EDT
C$0.05
>-C$0.01(-3.64%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)50.06K
Market Cap
C$3.06M
Enterprise ValueC$3.38
Total Cash (Recent Filing)C$25.13K
Total Debt (Recent Filing)C$40.00K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding61,246,628
10 Day Avg. Volume51,225
30 Day Avg. Volume50,057
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.51
Price to Sales (P/S)48.92
P/FCF Ratio-26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp Revenue ReboundThe strong TTM revenue rebound indicates improved product sales or distribution activity. If sustained, increasing commercial traction could provide a larger base for operating leverage, although the current scale remains modest.
Gross Margin RecoveryA return to positive gross margin suggests better pricing, product mix, or cost control at the gross-profit level. Sustaining this improvement would strengthen the economics of future growth and reduce reliance on low-margin sales.
Low Absolute DebtLimited debt reduces fixed financing obligations and refinancing exposure. This gives the company more flexibility than a highly leveraged device business, though liquidity remains constrained because operations still consume cash.
Bears Say
Large Persistent Net LossThe loss remains far larger than the current revenue base, showing that operating expenses are not yet supported by commercial activity. Continued losses could delay breakeven, require additional funding, and limit investment in product development.
Negative Operating Cash FlowOngoing cash consumption means reported revenue growth has not yet translated into self-funded operations. Until cash flow turns sustainably positive, the company remains exposed to liquidity pressure and potential dependence on external capital.
Negative Equity And Limited Capital BaseNegative equity reflects accumulated losses and weakens the balance sheet’s capacity to absorb further setbacks. The small asset base also limits financial flexibility, increasing the likelihood that growth or ongoing operations may need outside funding.
Therma Bright News
THRM FAQ
What was Therma Bright’s price range in the past 12 months?
Therma Bright lowest stock price was C$0.04 and its highest was C$0.12 in the past 12 months.
What is Therma Bright’s market cap?
Therma Bright’s market cap is C$3.06M.
When is Therma Bright’s upcoming earnings report date?
Therma Bright’s upcoming earnings report date is Dec 01, 2026 which is in 100 days.
How were Therma Bright’s earnings last quarter?
Therma Bright released its earnings results on Jun 25, 2026. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Therma Bright overvalued?
According to Wall Street analysts Therma Bright’s price is currently Overvalued.
Does Therma Bright pay dividends?
Therma Bright does not currently pay dividends.
What is Therma Bright’s EPS estimate?
Therma Bright’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Therma Bright have?
Therma Bright has 61,246,628 shares outstanding.
What happened to Therma Bright’s price movement after its last earnings report?
Therma Bright reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Therma Bright?
Currently, no hedge funds are holding shares in TSE:THRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Therma Bright
Established in Toronto, Canada, in 2001 as The Jenex Corporation before rebranding to Therma Bright Inc. in February 2018, Therma Bright Inc. specializes in creating and distributing various medical and consumer health products. Their diverse offerings include rapid COVID-19 diagnostic tests like AcuVid, which screens for both antigens and antibodies. For pain relief, they provide devices such as Benepod, a hot and cold contrast therapy system designed to manage discomfort without medication. The company also addresses circulatory issues with Venowave, a medical compression pump aimed at mitigating symptoms associated with poor circulation. Furthermore, Therma Bright caters to the cosmeceutical industry with products like InterceptCS, a cold sore prevention system utilizing safe, controlled topical heat, and TherOZap, a thermal device that alleviates the pain, itching, and inflammation from insect bites and stings by reducing the inflammatory response. Their clientele spans both individual consumers and healthcare practitioners.
Technical Analysis
―
Perimeter Medical Imaging AI
―
Profound Medical
―
Theralase Technologies
―
Aquarius Surgical Technologies
―